Senescence-associated inflammatory responses: Aging and cancer perspectives

Trends in Immunology

Volumn 36, Issue 4, 2015, Pages 217-228

  Lasry, Audrey ^a   Ben Neriah, Yinon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Aging; Cancer; Inflammation; Parainflammation; SASP SIR; Senescence

Indexed keywords

AGING; CANCER CONTROL; IMMUNOCOMPETENT CELL; INFLAMMATION; MEDIATOR RELEASE; NONHUMAN; REVIEW; SENESCENCE; TUMOR IMMUNITY; TUMOR INVASION; TUMOR MICROENVIRONMENT; HUMAN; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

AGING; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 84926523961     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.02.009     Document Type: Review

References (147)

1. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25:585-621.
2. Baker D.J., et al. Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat. Cell Biol. 2008, 10:825-836.
3. Munoz-Espin D., et al. Programmed cell senescence during mammalian embryonic development. Cell 2013, 155:1104-1118.
4. Rajagopalan S., Long E.O. Cellular senescence induced by CD158d reprograms natural killer cells to promote vascular remodeling. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20596-20601.
5. Storer M., et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 2013, 155:1119-1130.
6. Chuprin A., et al. Cell fusion induced by ERVWE1 or measles virus causes cellular senescence. Genes Dev. 2013, 27:2356-2366.
7. Jun J.I., Lau L.F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat. Cell Biol. 2010, 12:676-685.
8. Krizhanovsky V., et al. Senescence of activated stellate cells limits liver fibrosis. Cell 2008, 134:657-667.
9. Serrano M., et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88:593-602.
10. Xue W., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
11. Rielland M., et al. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. J. Clin. Invest. 2014, 124:2125-2135.
12. Rodier F., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat. Cell Biol. 2009, 11:973-979.
13. Yoshimoto S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
14. Coppe J.P., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008, 6:2853-2868.
15. Kuilman T., Peeper D.S. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 2009, 9:81-94.
16. Pribluda A., et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 2013, 24:242-256.
17. Krtolica A., et al. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:12072-12077.
18. Bavik C., et al. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006, 66:794-802.
19. Ohuchida K., et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 2004, 64:3215-3222.
20. Blackburn E.H. Structure and function of telomeres. Nature 1991, 350:569-573.
21. Reaper P.M., et al. Activation of the DNA damage response by telomere attrition: a passage to cellular senescence. Cell Cycle 2004, 3:543-546.
22. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 2009, 9:749-758.
23. Kim W.Y., Sharpless N.E. The regulation of INK4/ARF in cancer and aging. Cell 2006, 127:265-275.
24. Chicas A., et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010, 17:376-387.
25. Kim N.W., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
26. Shay J.W., Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 1997, 33:787-791.
27. Hollstein M., et al. p53 mutations in human cancers. Science 1991, 253:49-53.
28. Foster S.A., et al. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 1998, 18:1793-1801.
29. Jarrard D.F., et al. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells. Cancer Res. 1999, 59:2957-2964.
30. Braig M., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
31. Michaloglou C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
32. Collado M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
33. Chen Z., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
34. Courtois-Cox S., et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
35. Sarkisian C.J., et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 2007, 9:493-505.
36. Dhomen N., et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009, 15:294-303.
37. Kuilman T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
38. Kaplon J., et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 2013, 498:109-112.
39. Vredeveld L.C., et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012, 26:1055-1069.
40. Shamma A., et al. Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 2009, 15:255-269.
41. Alimonti A., et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J. Clin. Invest. 2010, 120:681-693.
42. Dirac A.M., Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 2003, 278:11731-11734.
43. Sage J., et al. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 2003, 424:223-228.
44. Brugarolas J., et al. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552-557.
45. Deng C., et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
46. Wang C., et al. DNA damage response and cellular senescence in tissues of aging mice. Aging Cell 2009, 8:311-323.
47. Krishnamurthy J., et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453-457.
48. Beausejour C.M., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 2003, 22:4212-4222.
49. Narita M., et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003, 113:703-716.
50. Di Micco R., et al. Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat. Cell Biol. 2011, 13:292-302.
51. Chen Q., Ames B.N. Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:4130-4134.
52. Chen Q.M., et al. Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. Exp. Cell Res. 2001, 265:294-303.
53. Denoyelle C., et al. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 2006, 8:1053-1063.
54. Parrinello S., et al. Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat. Cell Biol. 2003, 5:741-747.
55. Severino J., et al. Is beta-galactosidase staining a marker of senescence in vitro and in vivo?. Exp. Cell Res. 2000, 257:162-171.
56. Dimri G.P., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9363-9367.
57. Kurz D.J., et al. Senescence-associated (beta)-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Sci. 2000, 113:3613-3622.
58. Georgakopoulou E.A., et al. Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging 2013, 5:37-50.
59. Zhang R., et al. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol. Cell. Biol. 2007, 27:2343-2358.
60. Kosar M., et al. Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle 2011, 10:457-468.
61. Shelton D.N., et al. Microarray analysis of replicative senescence. Curr. Biol. 1999, 9:939-945.
62. Coppe J.P., et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 2010, 5:99-118.
63. Acosta J.C., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
64. Chien Y., et al. Control of the senescence-associated secretory phenotype by NF-kappaB promotes senescence and enhances chemosensitivity. Genes Dev. 2011, 25:2125-2136.
65. Hubackova S., et al. IL1- and TGFbeta-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'bystander senescence'. Aging 2012, 4:932-951.
66. Acosta J.C., et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat. Cell Biol. 2013, 15:978-990.
67. Gross O., et al. Inflammasome activators induce interleukin-1alpha secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012, 36:388-400.
68. Orjalo A.V., et al. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:17031-17036.
69. Miao E.A., et al. Caspase-1-induced pyroptotic cell death. Immunol. Rev. 2011, 243:206-214.
70. Sagulenko V., et al. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ. 2013, 20:1149-1160.
71. Wu L., et al. Macrophage colony-stimulating factor accelerates wound healing and upregulates TGF-beta1 mRNA levels through tissue macrophages. J. Surg. Res. 1997, 72:162-169.
72. Gurtner G.C., et al. Wound repair and regeneration. Nature 2008, 453:314-321.
73. Pazolli E., et al. Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression. Cancer Res. 2012, 72:2251-2261.
74. Chen H., et al. Age-associated loss of lamin-B leads to systemic inflammation and gut hyperplasia. Cell 2014, 159:829-843.
75. Freund A., et al. Lamin B1 loss is a senescence-associated biomarker. Mol. Biol. Cell 2012, 23:2066-2075.
76. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
77. Naylor R.M., et al. Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin. Pharmacol. Ther. 2013, 93:105-116.
78. Huang S., et al. Correction of cellular phenotypes of Hutchinson-Gilford Progeria cells by RNA interference. Hum. Genet. 2005, 118:444-450.
79. Huang S., et al. Accelerated telomere shortening and replicative senescence in human fibroblasts overexpressing mutant and wild-type lamin A. Exp. Cell Res. 2008, 314:82-91.
80. Bernal G.M., et al. Loss of Nfkb1 leads to early onset aging. Aging 2014, 6:931-943.
81. Bergo M.O., et al. Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13049-13054.
82. Varela I., et al. Accelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation. Nature 2005, 437:564-568.
83. Liu B., et al. Genomic instability in laminopathy-based premature aging. Nat. Med. 2005, 11:780-785.
84. Osorio F.G., et al. Nuclear lamina defects cause ATM-dependent NF-kappaB activation and link accelerated aging to a systemic inflammatory response. Genes Dev. 2012, 26:2311-2324.
85. Tilstra J.S., et al. NF-kappaB inhibition delays DNA damage-induced senescence and aging in mice. J. Clin. Invest. 2012, 122:2601-2612.
86. Baker D.J., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479:232-236.
87. Klapper W., et al. Telomerase activity in 'immortal' fish. FEBS Lett. 1998, 434:409-412.
88. Klapper W., et al. Longevity of lobsters is linked to ubiquitous telomerase expression. FEBS Lett. 1998, 439:143-146.
89. Schmich J., et al. Induction of reverse development in two marine Hydrozoans. Int. J. Dev. Biol. 2007, 51:45-56.
90. Wenger Y., et al. Injury-induced immune responses in Hydra. Semin. Immunol. 2014, 26:277-294.
91. Bosch T.C. Rethinking the role of immunity: lessons from Hydra. Trends Immunol. 2014, 35:495-502.
92. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276:60-66.
93. Iakova P., et al. Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell 2003, 113:495-506.
94. Lazzerini Denchi E., et al. Hepatocytes with extensive telomere deprotection and fusion remain viable and regenerate liver mass through endoreduplication. Genes Dev. 2006, 20:2648-2653.
95. Gielchinsky Y., et al. Pregnancy restores the regenerative capacity of the aged liver via activation of an mTORC1-controlled hyperplasia/hypertrophy switch. Genes Dev. 2010, 24:543-548.
96. Zhu C., et al. Senescence-related genes possibly responsible for poor liver regeneration after hepatectomy in elderly patients. J. Gastroenterol. Hepatol. 2014, 29:1102-1108.
97. Nguyen L.N., et al. Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferation. Hepatology 2007, 45:31-41.
98. Cressman D.E., et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
99. Taub R., et al. Transcriptional regulatory signals define cytokine-dependent and -independent pathways in liver regeneration. Semin. Liver Dis. 1999, 19:117-127.
100. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 2012, 22:33-40.
101. Aggarwal B.B., et al. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009, 15:425-430.
102. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 2011, 12:715-723.
103. Grivennikov S.I., et al. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
104. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
105. Allavena P., et al. Chemokines in cancer related inflammation. Exp. Cell Res. 2011, 317:664-673.
106. Squires D.F. Neoplasia in a Coral?. Science 1965, 148:503-505.
107. Pankow S., Bamberger C. The p53 tumor suppressor-like protein nvp63 mediates selective germ cell death in the sea anemone Nematostella vectensis. PLoS ONE 2007, 2:e782.
108. Bennett D.C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 2003, 22:3063-3069.
109. Bennecke M., et al. Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 2010, 18:135-146.
110. Dilley T.K., et al. Novel mechanisms of sublethal oxidant toxicity: induction of premature senescence in human fibroblasts confers tumor promoter activity. Exp. Cell Res. 2003, 290:38-48.
111. Coppe J.P., et al. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J. Biol. Chem. 2006, 281:29568-29574.
112. Schmitt C.A., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
113. Elyada E., et al. CKIalpha ablation highlights a critical role for p53 in invasiveness control. Nature 2011, 470:409-413.
114. Fleischmann R. Anakinra in the treatment of rheumatic disease. Expert Rev. Clin. Immunol. 2006, 2:331-340.
115. Deisseroth A., et al. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin. Cancer Res 2015, Published online January 19, 2015. 10.1158/1078-0432.CCR-14-1678.
116. Karsdal M.A., et al. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin. Arthritis Rheum. 2012, 42:131-139.
117. Hashimoto J., et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod. Rheumatol. 2011, 21:10-15.
118. Heinrich P.C., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
119. Meyer D.M., et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J. Inflamm. 2010, 7:41.
120. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012, 119:2721-2730.
121. Quintas-Cardama A., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
122. Citro A., et al. CXCR1/2 inhibition blocks and reverts type 1 diabetes in mice. Diabetes 2014, Published online October 14, 2014. 10.2337/db14-0443.
123. Dorr J.R., et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013, 501:421-425.
124. Kang T.W., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
125. Ott P.A., et al. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin. Cancer Res. 2013, 19:5300-5309.
126. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971, 231:232-235.
127. Williams C., et al. The role of COX-2 in intestinal cancer. Ann. N. Y. Acad. Sci. 1999, 889:72-83.
128. Abrams P.H., Feneley R.C. The actions of prostaglandins on the smooth muscle of the human urinary tract in vitro. Br. J. Urol. 1975, 47:909-915.
129. Williams C.S., et al. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
130. Sheng H., et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 2001, 276:18075-18081.
131. Rothwell P.M., et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
132. Breitner J.C., et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimer's Dement. 2011, 7:402-411.
133. Waddell W.R., Loughry R.W. Sulindac for polyposis of the colon. J. Surg. Oncol. 1983, 24:83-87.
134. Piazza G.A., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997, 57:2909-2915.
135. Thun M.J., et al. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med. 1991, 325:1593-1596.
136. Sandler R.S., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348:883-890.
137. Fraser D.M., et al. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br. J. Cancer 2014, 111:623-627.
138. Streicher S.A., et al. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol. Biomarkers Prev. 2014, 23:1254-1263.
139. Ng K., et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J. Natl. Cancer Inst. 2015, 107:345.
140. Achiwa H., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. 1999, 5:1001-1005.
141. Komhoff M., et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am. J. Pathol. 2000, 157:29-35.
142. Tjandrawinata R.R., et al. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br. J. Cancer 1997, 75:1111-1118.
143. Koki A., et al. Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 2002, 507:177-184.
144. Herfs M., et al. Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation?. Trends Mol. Med. 2009, 15:245-253.
145. Liu X.H., et al. Prostaglandin E2 modulates components of the Wnt signaling system in bone and prostate cancer cells. Biochem. Biophys. Res. Commun. 2010, 394:715-720.
146. Liao X., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N. Engl. J. Med. 2012, 367:1596-1606.
147. Domingo E., et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J. Clin. Oncol. 2013, 31:4297-4305.